David V. Smith

Corporate finance veteran David V. Smith joined the company’s Board of Directors in 2021. Most recently, Mr. Smith served as Executive Vice President and Chief Financial Officer at Five Prime Therapeutics, a publicly traded company focused on discovering and developing novel immuno-oncology protein therapeutics, acquired by Amgen in April 2021. Previously, Mr. Smith served as Chief Operating Officer of IntegenX, and Chief Financial Officer of Thoratec, Chiron and Anergen, Inc. He has also held finance positions with Genentech, Inc., Syntex and IBM.

Mr. Smith is currently the Chair of the Audit and Strategy Committees of Codexis, Inc. Previously, he served as Chair of the Audit Committee and a Director of OncoGenex Pharmaceuticals, Inc., and of Perlegen Sciences, Inc.

Mr. Smith holds a B.A. in Economics and History from Willamette University and an M.B.A. specializing in Finance from Golden Gate University.